Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Average Target Price of $291.25 According to Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus rating of “Buy” from the twenty brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $291.25.

Several equities analysts have recently commented on the company. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a research note on Wednesday, August 26th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 3rd.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the sale, the director owned 345,875 shares of the company’s stock, valued at approximately $79,665,388.75. This trade represents a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total transaction of $486,060.00. Following the completion of the sale, the chief executive officer directly owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. The trade was a 1.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 100,121 shares of company stock worth $24,855,802 over the last quarter. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of JAZZ. USA Financial Formulas bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals during the third quarter worth approximately $32,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $47,000. Westpac Banking Corp bought a new position in shares of Jazz Pharmaceuticals during the first quarter worth approximately $51,000. Finally, Root Financial Partners LLC increased its holdings in shares of Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 89 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.0%

Shares of JAZZ opened at $210.23 on Thursday. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The firm has a market cap of $13.65 billion, a P/E ratio of 14.50, a price-to-earnings-growth ratio of 0.21 and a beta of 0.37. The firm’s 50-day simple moving average is $239.74 and its 200 day simple moving average is $231.93. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm’s revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($8.25) earnings per share. On average, analysts forecast that Jazz Pharmaceuticals will post 21.59 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.